← Eichor
Condition: Melanoma Stage Iii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Melanoma Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06594991BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Phase 3 · 30 location(s) · Canadian Cancer Trials Group · NCT02821013Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
EARLY_Phase 1 · 1 location(s) · Xijing Hospital · NCT07586904NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151FMT to Convert Response to Immunotherapy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05251389Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Phase 2 · 1 location(s) · University of California, Irvine · NCT06771544Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Phase N/A · 39 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT03605771Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Mela
Phase 3 · 15 location(s) · ETOP IBCSG Partners Foundation · NCT05522660Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
Phase 2 · 6 location(s) · UNICANCER · NCT07230613Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve
NA · 1 location(s) · Mayo Clinic · NCT07379138A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Phase N/A · 59 location(s) · Pierre Fabre Pharma GmbH · NCT04045691Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NA · 7 location(s) · Craig L Slingluff, Jr · NCT05839912Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the In
NA · 1 location(s) · D.J. (Dirk) Grünhagen · NCT06754904PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Phase 3 · 6 location(s) · Vastra Gotaland Region · NCT06519266Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT03941756Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06295159A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Phase 1/Phase 2 · 1 location(s) · University of Louisville · NCT01638676Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma
NA · 5 location(s) · Azienda Ospedaliera di Perugia · NCT07050940OH2 Injection in Melanoma
Phase 3 · 30 location(s) · Binhui Biopharmaceutical Co., Ltd. · NCT05868707Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Phase 2 · 2 location(s) · University of California, San Francisco · NCT04598009Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Phase 3 · 26 location(s) · Uppsala University · NCT06488482Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Phase N/A · 1 location(s) · Mayo Clinic · NCT06075524A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
NA · 20 location(s) · Uppsala University · NCT03116412Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.